Scientific Talks

Scientific Talks

Oct 18, 2014

Tissue Phenomics: From Biomarker Discovery to Clinical Diagnostic Assay Commercialization

Dr. Thomas Nifong, Executive Vice President, Diagnostic Tests, Definiens, Boston, Massachusetts, USA

Definiens’ Cognition Network Technology® (CNT) provides detailed tissue biomarker readouts from digital pathology slides, and enables the correlation of this information with clinical outcome and genomic data, an approach known as Tissue Phenomics. The manual approach to analyzing tissue provides mostly limited, qualitative information. However using CNT, thousands of quantitative,...

Read More
Oct 18, 2014

Tissue Quality and Clinical Data: The Bottleneck for Drug and Biomarker Development

Dr. Hartmut Juhl, Chief Executive Officer, Indivumed GmbH, Hamburg, Germany

Identification of drug targets as stratification and predictive biomarkers in patient populations by analyzing surgically resected tissues has become an important field in drug development. However, considerable research data demonstrate that RNA and protein expression level, including activation or inhibition of signaling pathways and their receptors can change significantly within...

Read More
Oct 18, 2014

Measurement of Target Engagement and Pharmacodynamic Response to Investigational Anti-Cancer Agents in Phase 1 Clinical Trials

Dr. Robert J. Kinders, Senior Principal Scientist and Head, Pharmacodynamics, Laboratory of Human Toxicology and Pharmacology, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA

Phase 1 Clinical trials of candidate anti-cancer agents are intended to establish the Maximum Tolerated Dose of the agent. In current practice, evidence of activity of the agent on the intended target is also a requirement in NCI-funded trials. The nature of these early clinical trial designs significantly impacts the...

Read More
Oct 18, 2014

Development of an Encapsulated Cell Replacement Therapy for Diabetes

Dr. Olivia G. Kelly, Director, Cell Biology, ViaCyte, Inc., San Diego, California, USA

ViaCyte Inc. is a clinical stage company developing a stem cell-based islet cell replacement therapy for treatment of patients with diabetes. The therapy is a combination product comprised of pancreatic progenitors, PEC-01™ cells, encapsulated within a retrievable delivery device, ENCAPTRAR Drug Delivery System. After implantation, encapsulated progenitor cells mature into...

Read More
Oct 18, 2014

Imaging and Analysis of RNA Biomarkers In Situ via RNAscope and SpotStudio

Dr. Xiao-Jun Ma, Chief Scientific Officer, Advanced Cell Diagnostics, Hayward, California, USA

RNA in situ hybridization (ISH) is a powerful tool for establishing spatial and cell type-specific gene expression in tissue. Traditional RNA ISH methods are technically challenging to perform and lack sufficient sensitivity and specificity for most clinically relevant biomarkers. RNAscope is a novel RNA ISH technology capable of detecting RNA...

Read More